Q-omics provides the consensus-scored MEIOSIN profile across patient tissues and cancer cell-line models. MEIOSIN expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MEIOSIN is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, MEIOSIN RNA expression shows 7,156 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, HNSC, and TGCT as cancer lineages where MEIOSIN shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MEIOSIN — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MEIOSIN survival associations across molecular data types. MEIOSIN RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MEIOSIN RNA expression–survival associations across cancer types. High MEIOSIN expression shows unfavorable associations in KIRC, MESO, LIHC, KIRP and THCA, but favorable associations in UCEC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MEIOSIN RNA expression.
This table summarizes MEIOSIN tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for MEIOSIN. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MEIOSIN shows higher tumor expression in HNSC, KIRP, COAD, BLCA, LUSC and BRCA. The HNSC box plot shows higher MEIOSIN RNA expression in tumor versus normal tissue (log2 FC = +0.158, t-test p < 0.001).
This table shows molecular features associated with MEIOSIN in patient tissues and cancer cell lines. In patient samples, MEIOSIN shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, MEIOSIN RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC.
